Group 1 - The medical sector continues to decline, with the largest medical ETF (512170) dropping by 2.44%, losing multiple moving averages [1] - Despite the decline, there is active low-buying interest, as evidenced by a net subscription of 1.07 billion yuan over six consecutive trading days [1] - Eight out of ten component stocks of the medical ETF have reported positive earnings forecasts for 2025, with seven stocks expected to achieve double-digit growth [2][3] Group 2 - Notable earnings growth includes a projected increase of 214% to 371% for Zhaoyan New Drug, and both Boteng Co. and WuXi AppTec are expected to double their profits [2][3] - The CXO industry is expected to benefit from a recovering global investment environment and continued domestic support for innovative drug development, indicating a positive trend for the sector [2] - The medical ETF (512170) has a total fund size of 26.8 billion yuan, making it the largest in the market for medical ETFs [6]
医疗再度走弱，512170续跌逾2%连失多根均线！成份股批量业绩预喜，逾10亿元资金坚定逆行
Xin Lang Ji Jin·2026-01-27 02:17